AppyScore™ blood-based diagnostic test for appendicitis

Checked on September 30, 2026. The cited source supports part of this claim, but not all of it.

The filing confirms AppyScore's purpose as a blood-based test to help ER physicians identify low-risk appendicitis patients. It describes the test as still in development, not as already developed.

Confirmed in the source:

• AppyScore is the company's blood-based diagnostic test for appendicitis
• The test is designed to aid emergency room physicians and other practitioners in identifying patients at low risk for acute appendicitis

We could not confirm this from the cited source:

• That the company has finished developing AppyScore; the filing calls it a product candidate still in development, with remaining development and clinical trial work needed

That does not mean it is false — only that this source does not establish it, as of the date above. If we find a source that settles it, we will re-check and update this page.

What we did: Read our cached copy of SEC EDGAR (https://www.sec.gov/Archives/edgar/data/1167419/000107997312000796/appy_def14a.htm) in full (92,836 characters, retrieved September 27, 2026) and checked each assertion in the claim against it.

confirms Riot DEF 14A filed 2012-10-15

Quote: “the Company's blood-based diagnostic test to aid emergency room physicians and other practitioners in the identification of patients at low risk for acute appendicitis, allowing for more conservative patient management”

View cached copy (2026-09-27)Live source ↗